Shots:
- Formycon has signed a settlement and license agreement with Regeneron and Bayer for the commercialization of FYB203, a biosimilar version of Eylea 2 mg (aflibercept 0.05 ml of 40 mg/mL solution), in the EU
- Under the agreement, both products may launch in the EU and other regions, including LATAM and Asia-Pacific, from May 2026. Earlier, in October 2025, Formycon secured a US license date for FYB203 in Q4’26 under its agreement with Regeneron
- Ahzantive & Baiama (aflibercept) inhibits VEGF, preventing abnormal blood vessel growth in the retina that can lead to vision loss, and was approved in the EC for treating nAMD and other serious retinal diseases
Ref: Formycon | Image: Formycon, Regeneron, and Bayer | Press Release
Related News: Formycon and Zydus Lifescience Report Successful Clinical Development of FYB206 (Biosimilar, Keytruda)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
